Clene Inc. (CLNN) Stock

Clene Inc. (CLNN) is a Healthcare stock trading at $4.37 (as of 2026-08-21), with a market capitalization of $56.15M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Clene Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing clean-surfaced nanotechnology (CSN) therapeutics. Its product pipeline includes CNM-Au8 for neurological indications such as ALS and chronic optic neuropathy, and other CSN candidates including CNM-AgZn17 and CNM-ZnAg for infectious disease and wound-related uses.

Understand Clene Inc.: how it makes money

Clene Inc. develops and commercializes clean-surfaced nanotechnology (CSN) therapeutics, led by CNM-Au8 for amyotrophic lateral sclerosis (ALS), and it makes money through potential product revenue and royalty revenue.

Because Clene is a clinical-stage pharmaceutical company, its profit model depends on CNM-Au8 progressing toward registrational results and commercialization, which would be reflected only later in product and/or royalty revenue (currently both are 0).

Revenue by segment (latest quarter)
Product$0.0B
Royalties$0.0B

Business quality (Weak): Clear focus on CNM-Au8 across ALS clinical programs, but the latest quarter shows no product or royalty revenue, so progress hinges on upcoming clinical and regulatory milestones rather than current commercial traction.

Bull case

  • Regulatory-focused ALS program underway: CNM-Au8 is being studied in a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS), and Clene also completed a Phase 2 proof of concept trial in early symptomatic ALS.
  • Broader patient access and treatment evidence from programs: Clene reports 800 patients treated with CNM-Au8, and 200 people living with ALS treated under the National Institutes of Health-sponsored Expanded Access Program.

Bear case

  • No commercial revenue yet: In the latest quarter (period ending 2026-03-31), product revenue and royalty revenue are both 0.0B, meaning financial results are not yet supported by sales.
  • Profitability is deeply negative: The company reports an operating margin of -13740.0% for the period ending 2026-03-31.
Valuation — source: SEC EDGAR (first-party)
Price$4.37
Market Cap$56.15M
Price / Sales415.91
FCF Yield-37.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$200000.00
Net Margin-13086.5%
Revenue Growth (YoY)-41.5%
EPS Growth (YoY)-53.3%
FCF Growth (YoY)-12.9%
Financial Health — source: SEC EDGAR
Altman Z-Score-27.25 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBoxer Capital Management, LLC ($2.35M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORobert Etherington
Employees75
CountryUS
IPO Date2018-10-18

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Heron Therapeutics, Inc. (HRTX)
  • Talphera, Inc. (TLPH)
  • RenovoRx, Inc. (RNXT)
  • Stablecoin Development Corp (SDEV)
  • Context Therapeutics Inc. (CNTX)
  • Xilio Therapeutics, Inc. (XLO)
  • Impact BioMedical Inc. (IBO)
  • TransCode Therapeutics, Inc. (RNAZ)
CLNN earnings history · CLNN institutional & insider holders · CLNN KPIs & operating metrics · CLNN financials · CLNN investor presentations & press releases · CLNN SEC filings · CLNN peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.